259 related articles for article (PubMed ID: 34047517)
21. Efficacy of humanized carbapenem and ceftazidime regimens against Enterobacteriaceae producing OXA-48 carbapenemase in a murine infection model.
Wiskirchen DE; Nordmann P; Crandon JL; Nicolau DP
Antimicrob Agents Chemother; 2014; 58(3):1678-83. PubMed ID: 24379200
[TBL] [Abstract][Full Text] [Related]
22. First Clinical Cases of KPC-2-Producing
Brahmia S; Lalaoui R; Nedjai S; Djahmi N; Chettibi S; Rolain JM; Bakour S
Microb Drug Resist; 2021 May; 27(5):652-659. PubMed ID: 32991248
[No Abstract] [Full Text] [Related]
23. [Evaluation of In Vitro Efficacy of Ceftazidime-Avibactam, Meropenem, and Colistin Single and Binary Combinations Against Carbapenem Resistant Klebsiella pneumoniae Strains Isolated from Various Clinical Specimens].
Köle M; Sesli Çetin E; Şirin MC; Cicioğlu Arıdoğan B
Mikrobiyol Bul; 2022 Apr; 56(2):230-250. PubMed ID: 35477227
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of humanized carbapenem exposures against New Delhi metallo-β-lactamase (NDM-1)-producing enterobacteriaceae in a murine infection model.
Wiskirchen DE; Nordmann P; Crandon JL; Nicolau DP
Antimicrob Agents Chemother; 2013 Aug; 57(8):3936-40. PubMed ID: 23733463
[TBL] [Abstract][Full Text] [Related]
25. [The Epidemiology of Carbapenemases in Escherichia coli and Klebsiella pneumoniae Isolated in 2019 in Turkey].
Süzük Yıldız S; Şimşek H; Bakkaloğlu Z; Numanoğlu Çevik Y; Hekimoğlu CH; Kılıç S; Alp Meşe E;
Mikrobiyol Bul; 2021 Jan; 55(1):1-16. PubMed ID: 33590977
[TBL] [Abstract][Full Text] [Related]
26. Study of
Zhang W; Guo Y; Yang Y; Dong D; Zheng Y; Zhu D; Hu F
Microb Drug Resist; 2020 Mar; 26(3):204-210. PubMed ID: 31553260
[No Abstract] [Full Text] [Related]
27. [Investigation of the susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. strains to ertapenem and other carbapenems].
Kuzucu C; Yetkin F; Görgeç S; Ersoy Y
Mikrobiyol Bul; 2011 Jan; 45(1):28-35. PubMed ID: 21341156
[TBL] [Abstract][Full Text] [Related]
28. Will ceftazidime/avibactam plus aztreonam be effective for NDM and OXA-48-Like producing organisms: Lessons learnt from
Pragasam AK; Veeraraghavan B; Shankar BA; Bakthavatchalam YD; Mathuram A; George B; Chacko B; Korula P; Anandan S
Indian J Med Microbiol; 2019; 37(1):34-41. PubMed ID: 31424008
[TBL] [Abstract][Full Text] [Related]
29. Investigation of in vitro efficacy of quercetin-meropenem combination in carbapenemase-producing Klebsiella pneumoniae isolates.
Aydemir Ö; Ormanoğlu G; Ayhancı T; Zengin M; Köroğlu M
J Infect Dev Ctries; 2023 Sep; 17(9):1325-1329. PubMed ID: 37824360
[TBL] [Abstract][Full Text] [Related]
30. Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09.
Davies TA; Marie Queenan A; Morrow BJ; Shang W; Amsler K; He W; Lynch AS; Pillar C; Flamm RK
J Antimicrob Chemother; 2011 Oct; 66(10):2298-307. PubMed ID: 21775338
[TBL] [Abstract][Full Text] [Related]
31. In vivo efficacy of human simulated regimens of carbapenems and comparator agents against NDM-1-producing Enterobacteriaceae.
Wiskirchen DE; Nordmann P; Crandon JL; Nicolau DP
Antimicrob Agents Chemother; 2014; 58(3):1671-7. PubMed ID: 24379195
[TBL] [Abstract][Full Text] [Related]
32. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay.
Pournaras S; Vrioni G; Neou E; Dendrinos J; Dimitroulia E; Poulou A; Tsakris A
Int J Antimicrob Agents; 2011 Mar; 37(3):244-7. PubMed ID: 21236643
[TBL] [Abstract][Full Text] [Related]
33. Activity of Ceftazidime-Avibactam Alone and in Combination with Ertapenem, Fosfomycin, and Tigecycline Against Carbapenemase-Producing
Ojdana D; Gutowska A; Sacha P; Majewski P; Wieczorek P; Tryniszewska E
Microb Drug Resist; 2019 Nov; 25(9):1357-1364. PubMed ID: 31295055
[TBL] [Abstract][Full Text] [Related]
34. Phenotypic, molecular, and in silico characterization of coumarin as carbapenemase inhibitor to fight carbapenem-resistant Klebsiella pneumoniae.
Abdel-Halim MS; El-Ganiny AM; Mansour B; Yahya G; Latif HKAE; Askoura M
BMC Microbiol; 2024 Feb; 24(1):67. PubMed ID: 38413891
[TBL] [Abstract][Full Text] [Related]
35. The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic model.
Deris ZZ; Yu HH; Davis K; Soon RL; Jacob J; Ku CK; Poudyal A; Bergen PJ; Tsuji BT; Bulitta JB; Forrest A; Paterson DL; Velkov T; Li J; Nation RL
Antimicrob Agents Chemother; 2012 Oct; 56(10):5103-12. PubMed ID: 22802247
[TBL] [Abstract][Full Text] [Related]
36. [Preliminary study on resistance mechanism and virulence features in carbapenems-resistant
Chen Z; Xiang J
Zhonghua Shao Shang Za Zhi; 2018 Nov; 34(11):796-801. PubMed ID: 30481921
[No Abstract] [Full Text] [Related]
37. Effectiveness of a double-carbapenem regimen for infections in humans due to carbapenemase-producing pandrug-resistant Klebsiella pneumoniae.
Giamarellou H; Galani L; Baziaka F; Karaiskos I
Antimicrob Agents Chemother; 2013 May; 57(5):2388-90. PubMed ID: 23439635
[TBL] [Abstract][Full Text] [Related]
38. Distribution of β-lactamase genes among carbapenem-resistant Klebsiella pneumoniae strains isolated from patients in Turkey.
Iraz M; Özad Düzgün A; Sandallı C; Doymaz MZ; Akkoyunlu Y; Saral A; Peleg AY; Özgümüş OB; Beriş FŞ; Karaoğlu H; Çopur Çiçek A
Ann Lab Med; 2015 Nov; 35(6):595-601. PubMed ID: 26354347
[TBL] [Abstract][Full Text] [Related]
39. Dissemination of Carbapenem-resistant Klebsiella pneumoniae clinical isolates with various combinations of Carbapenemases (KPC-2, NDM-1, NDM-4, and OXA-48) and 16S rRNA Methylases (RmtB and RmtC) in Vietnam.
Tada T; Tsuchiya M; Shimada K; Nga TTT; Thu LTA; Phu TT; Ohmagari N; Kirikae T
BMC Infect Dis; 2017 Jul; 17(1):467. PubMed ID: 28676118
[TBL] [Abstract][Full Text] [Related]
40. Underlying mechanisms of carbapenem resistance in extended-spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli isolates at a tertiary care centre in Lebanon: role of OXA-48 and NDM-1 carbapenemases.
Baroud M; Dandache I; Araj GF; Wakim R; Kanj S; Kanafani Z; Khairallah M; Sabra A; Shehab M; Dbaibo G; Matar GM
Int J Antimicrob Agents; 2013 Jan; 41(1):75-9. PubMed ID: 23142087
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
